DAIC

MAY 31, 2024

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. in 2024 and approximately $0.17

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

DAIC

APRIL 5, 2024

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need.

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

Cardiometabolic Health Congress

NOVEMBER 22, 2024

From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Lancet Commission on Obesity: The Lancet Diabetes & Endocrinology journal has accepted the Lancet Commission on Obesity’s report for publication, scheduled for early 2025, announced Robert H.

Blood Pressure 52

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 52